Amicus Therapeutics (FOLD) Earnings Date, Estimates & Call Transcripts $6.67 -0.01 (-0.15%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$6.63 -0.04 (-0.54%) As of 05/2/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Amicus Therapeutics Earnings Summary Latest Q2 Earnings DateAug. 8EstimatedConsensus EPS (Aug. 8) -$0.05 Actual EPS (Aug. 8) -$0.05 Actual Revenue (Aug. 8) $126.67MAmicus Therapeutics released Q2 2024 earnings on August 8, 2024, reporting an EPS of -$0.05, which hit the consensus estimate of -$0.05. Quarterly revenue rose 34.0% year-over-year to $126.67 million, above analysts' expectations of $121.21 million. With a trailing EPS of -$0.18, Amicus Therapeutics' earnings are expected to grow 186.67% next year, from $0.15 to $0.43 per share. Q2 2024 Earnings ResourcesQ2 2024 Earnings ReportConference Call Transcript & Audio Quarterly Report (10-Q) Slide Deck Press Release (8-K)Slide DeckFull Screen Slide DeckPowered by Get Amicus Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amicus Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataFOLD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.FOLD Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Amicus Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue GuidanceQ1 20252-$0.05-$0.01-$0.03Q2 20252-$0.01$0.01$0.00Q3 20251$0.04$0.04$0.04Q4 20252$0.07$0.10$0.09 FY 2025 7 $0.05 $0.14 $0.10 Q1 20261$0.06$0.06$0.06Q2 20261$0.07$0.07$0.07Q3 20261$0.11$0.11$0.11Q4 20261$0.13$0.13$0.13 FY 2026 4 $0.37 $0.37 $0.37 Q1 20271$0.10$0.10$0.10 Amicus Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/8/2024Q2 2024-$0.05-$0.05-$0.07$121.21M$126.67M5/9/2024Q1 2024-$0.06-$0.02+$0.04$0.12$111.19M$110.40M2/28/2024Q4 2023-$0.06-$0.11 -$0.05-$0.11$115.11M$115.08M11/8/2023Q3 2023-$0.08-$0.07+$0.01-$0.07$102.30M$103.50M8/8/2023Q2 2023-$0.12-$0.15 -$0.03-$0.15$89.57M$94.50M5/10/2023Q1 2023-$0.13-$0.18 -$0.05-$0.18$82.14M$86.27M Amicus Therapeutics Earnings - Frequently Asked Questions When did Amicus Therapeutics announce their last quarterly earnings? Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earning data on Thursday, August 8, 2024. Learn more on FOLD's earnings history. What guidance has Amicus Therapeutics issued on next quarter's earnings? Amicus Therapeutics updated its FY 2025 earnings guidance on Thursday, May, 1st. The company issued revenue guidance of $607.5 million-$644.5 million, compared to the consensus revenue estimate of $631.2 million. Did Amicus Therapeutics beat their earnings estimates last quarter? In the previous quarter, Amicus Therapeutics (NASDAQ:FOLD) reported ($0.05) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.05). Learn more on analysts' earnings estimate vs. FOLD's actual earnings. How can I listen to Amicus Therapeutics's earnings conference call? The conference call for Amicus Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Amicus Therapeutics's conference call transcript? The conference call transcript for Amicus Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Amicus Therapeutics generate each year? Amicus Therapeutics (NASDAQ:FOLD) has a recorded annual revenue of $528.30 million. How much profit does Amicus Therapeutics generate each year? Amicus Therapeutics (NASDAQ:FOLD) has a recorded net income of -$151.58 million. FOLD has generated -$0.18 earnings per share over the last four quarters. What is Amicus Therapeutics's price-to-earnings ratio? Amicus Therapeutics (NASDAQ:FOLD) has a forward price-to-earnings ratio of 44.47. The price/earnings-to-growth ratio is 1.51. What is Amicus Therapeutics's EPS forecast for next year? Amicus Therapeutics's earnings are expected to grow from $0.15 per share to $0.43 per share in the next year, which is a 186.67% increase. More Earnings Resources from MarketBeat Related Companies Exact Sciences Earnings Date Repligen Earnings Date Halozyme Therapeutics Earnings Date Madrigal Pharmaceuticals Earnings Date Ionis Pharmaceuticals Earnings Date Alkermes Earnings Date Ligand Pharmaceuticals Earnings Date BioCryst Pharmaceuticals Earnings Date MannKind Earnings Date Celldex Therapeutics Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernVisa Q2 Earnings Top Forecasts, Adds $30B Buyback PlanMicrosoft Crushes Earnings, What’s Next for MSFT Stock?Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay AwayAMD Stock Signals Strong Buy Ahead of Earnings This page (NASDAQ:FOLD) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
